ATG-021 / Antengene - LARVOL DELTA

ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release (SITC 2023) - "Results Compared to clinical benchmark TCE, Talquetamab and RG2634, ATG-021 has a higher affinity to GPRC5D positive cells. Notably, the serum concentration of proinflammatory cytokines, such as IL-2, INF-γ, and TNF-α, were significantly lower in ATG-021 treated group, suggesting low risk of cytokine release syndrome (figure 2). Conclusions The result demonstrates the optimum efficacy and safety of ATG-021 which warrants further clinical evaluation against MM."

IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • GPRC5D • IL2 • TNFA

Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it has presented results from five programs by poster presentation...at the 2023 Society of Immunology in Cancer Annual Meeting (SITC 2023)....As a novel 2+1 GPRC5DxCD3 T cell engager, ATG-021 has demonstrated optimum efficacy and safety through its GPRC5D-dependent CD3 binding. It has demonstrated potent in vivo anti-tumor efficacy with reduced cytokine release in pre-clinical studies. These pre-clinical data warrant further clinical evaluation of ATG-021 against multiple myeloma."

Preclinical • Multiple Myeloma

Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting (SITC 2023) to be held in San Diego from November 1-5, 2023....The presentations feature five Antengene's clinical and preclinical programs, including two clinical programs, the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101; two preclinical programs, the LILRB4 antagonist antibody ATG-034 and the GPRC5D/CD3 T-cell engager ATG-021; as well as the proprietary novel AnTenGager™ platform."

Clinical data • Preclinical